



1/16/2024

## Essential Health Benefit Formulary Updates

December 2023

The changes below are reflective of OptumRx P&T Committee decisions.

### 2023 FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective Date
Angioedema Agent	<b>Veopoz</b> (pozelimab-bbfg)	Tier 4 PA	1/1/2024
Gastrointestinal Agent	<b>Rebyota</b> (fecal microbiota, live-jslm)	Tier 4 PA	1/1/2024
Oncology	<b>Xeloda</b> (capecitabine)	PA Removed	1/1/2024

### YEAR-TO-DATE FORMULARY GENERIC RELEASES

**Generic drug is available at copay listed once drug is available on the market**

Therapeutic Class	Generic Name	For Brand Name	Formulary Status	Available Date
Substance Abuse	Naloxone nasal spray (OTC)	<b>Narcan</b>	Tier 1	12/1/2023
ADHD Agent	lisdexamfetamine capsule and chewable tablet	<b>Vyvanse</b>	Tier 1	8/28/2023
Respiratory Agent	tiotropium bromide capsule	<b>Spiriva</b>	Tier 2	9/6/2023
Antiretroviral Agent	darunavir tablet	<b>Prezista</b>	Tier 1	6/2/2023
Succinimide Agent	methsuximide	<b>Celontin</b>	Tier 1	5/12/2023
Antiasthmatic/ Bronchodilator Agents	budesonide rectal foam 2mg/act	<b>Uceris</b>	Tier 1	4/14/2023
Antifungal Agents	naftifine gel 2%	<b>Naftin</b>	Tier 2	4/20/2023

**Key**

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit CM=Oral Chemo  
 Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status.

Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

EHB Provider Formulary Updates 2022

Essential Health Benefit (EHB) Formulary Changes

2

## YEAR-TO-DATE FORMULARY GENERIC RELEASES

**Generic drug is available at copay listed once drug is available on the market**

Therapeutic Class	Generic Name	For Brand Name	Formulary Status	Available Date
Antiseizure Agents	primidone tablet 125mg	<b>Mysoline</b>	Tier 1	4/13/2023
Central Nervous System Stimulant	amphetamine-dextroamphetamine 24h ER capsules 25mg	<b>Adderall XR</b>	Tier 3	4/13/2023
Central Nervous System Agents	riluzole 50mg tablet	<b>Rilutek</b>	Tier 3 PA QL	2/1/2023

## YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective date
Antibacterial	<b>Humatin 250mg capsule (paromomycin)</b>	Tier 2	12/1/2023
Respiratory Agent	<b>Breo Ellipta (fluticasone-vilanterol) inhaler 50-25mcg</b>	PA, QL Added	10/10/2023
Diabetic Monitoring	<b>Dexcom g6 receiver</b>	Tier 2 PA	11/1/2023
	<b>Dexcom g6 sensor</b>	Tier 2 PA	11/1/2023
	<b>Dexcom g6 transmitter</b>	Tier 2 PA	11/1/2023
	<b>Dexcom g7 receiver</b>	Tier 2 PA	11/1/2023

	<b>Dexcom g7 sensor</b>	Tier 2 PA	11/1/2023
	<b>Guardian 4 glucose sensor</b>	Tier 3 PA	11/1/2023
	<b>Guardian Connect transmitter kit</b>	Tier 3 PA	11/1/2023
	<b>Guardian Link 3 transmitter kit</b>	Tier 3 PA	11/1/2023
	<b>Guardian 3 glucose sensor</b>	Tier 3 PA	11/1/2023
Oncology	<b>Mekinist (trametinib)</b> .05mL solution <b>Tafinlar (dabrafenib)</b> 10mg tablets	Tier 4 PA Added	10/1/2023
Vaccines	<b>Abrysvo</b> <b>Arexvy</b>	Tier 3 Added Preventive - AL, QL	11/16/2023
Anti-Infective Agent	<b>Beyfortus (niservimab-alip)</b> IM injection	Tier 2 Preventive AL, QL	9/28/2023
Blood Modifiers	<b>Mozobil (plerixafor)</b>	PA Removed	11/1/2023
Blood Modifiers	<b>plerixafor</b>	PA Removed	11/1/2023
Antidiabetic Agents	<b>Farxiga (dapagliflozin)</b> tablet	ST Removed	9/1/2023
Antidiabetic Agents	<b>Glyxambi (empagliflozin-linagliptin)</b> tablet	ST Removed	9/1/2023
Antidiabetic Agents	<b>Jardiance (empagliflozin)</b> tablet	ST Removed	9/1/2023

Antidiabetic Agents	<b>Synjardy &amp; Synjardy XR (empagliflozin-metformin) tablet</b>	ST Removed	9/1/2023
Antidiabetic Agents	<b>Xigduo XR (dapagliflozin-metformin) tablet</b>	ST Removed	9/1/2023
Antidiabetic Agents	<b>ciprofloxacin 0.2% otic solution</b>	ST Removed	9/1/2023
Anticoagulant	<b>enoxaparin SC injection</b> <b>fondaparinux SC injection</b>	QL Removed	10/1/2023
Antibacterial Agent	<b>Vancomycin 25mg/mL solution</b>	Tier 3	8/15/2023
Hormone Modifying Agent	<b>Omnitrope (somatropin) SC injection</b>	Tier 4 PA	8/15/2023
Dermatological Agents	<b>Adapalene cream and gel</b>	PA Removed	8/1/2023
Antipsychotics	<b>Invega Halfyera</b>	Tier 3	1/1/2024
Musculoskeletal Agents	<b>adaliumab-adaz SC injection</b> <b>Cyltezo (adalimumab-adbm) SC injection</b> <b>Hyrimoz (adalimumab-adaz) SC injection</b>	Tier 4 PA, QL Added (1/1/2024)	7/1/2023
Anti-Diabetics	<b>Mounjaro</b>	Tier 2 PA Added	1/1/2024
Complement C3 Inhibitor	<b>Syfovre (pegcetacoplan) 15mg/0.1mL intravitreal solution</b>	Tier 4 PA	7/1/2023
Nuclear Factor Erythyroid 2-Related Factor 2 Activator	<b>Skyclarys (omaveloxolone) 50mg capsule</b>	Tier 4 PA	7/1/2023
Antiparkinson Agent	<b>Neupro (rotigotine) 24hr patches</b>	ST Removed	6/1/2023

**Key**

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit CM=Oral Chemo  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status.  
Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents  
for additional information.  
This list does not guarantee coverage.

*EHB Provider Formulary Updates 2022*

**YEAR-TO-DATE FORMULARY CHANGES**

<b>Therapeutic Class</b>	<b>Medication</b>	<b>Formulary Changes</b>	<b>Effective date</b>
Disease Modifying Antirheumatic Agents	<b>Amjevita 10mg/0.2mL injection</b>	Tier 4 PA, QL	5/16/2023
Antineoplastics	<b>Orserdu (elacestrant hcl) tablets</b>	Tier 4 PA	6/1/2023
Hormonal Agents, Suppressant	<b>Lupron Depot Pediatric Kit 45mg</b>	Tier 4 PA	5/16/2023
Antineoplastic	<b>Farydak</b>	Remove PA	4/1/2023
Dermatological Agents	<b>Isotretinoin</b>	Remove PA	5/1/2023
	<b>Tretinoin</b>	Remove PA	
ADHD Agents	<b>Adderall IR (Brand)</b>	Tier 3	3/10/2022 to 1/1/2024
Antidiabetic Agents	<b>Ozempic Inj 2mg/3mL</b>	Tier 2 ST, QL	1/5/2023
Antineoplastics	<b>Turalio Cap 125mg</b>	Tier 4 PA	1/4/2023
GI Drugs Miscellaneous	<b>Skyrizi Inj 180/1.2</b>	Tier 4 PA	1/11/2023
Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment	<b>Tegsedi injection 284mg/1.5mL</b>	Add QL	1/1/2024
Gastrointestinal Agents	<b>Suprep Bowel Sol Prep Kit</b>	Excluded	1/1/2024
Antineoplastic Agents	<b>Revlimid capsule</b>	Tier 4 PA	1/1/2023
Vaccines	<b>Priorix injection</b>	Tier 2	1/1/2023
Analgesics	<b>Duramorph inj 0.5mg/mL</b>	Excluded	1/1/2024
Antibacterials	<b>Vandazole gel 0.75%</b>	Excluded	1/1/2024
Blood Products and Modifiers	<b>Pradaxa caps</b>	Excluded QL	1/1/2024
Dermatological Agents	<b>Crotan lot 10%</b>	Excluded	1/1/2024

**Key**

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit CM=Oral Chemo  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status.

Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

**YEAR-TO-DATE FORMULARY CHANGES**

<b>Therapeutic Class</b>	<b>Medication</b>	<b>Formulary Changes</b>	<b>Effective date</b>
Antineoplastics	<b>Rubraca tab</b>	Excluded PA	1/1/2024
Antibacterials	<b>Xifaxan tab 200mg</b>	Excluded PA	1/1/2024
Electrolytes/Minerals/Metals/ Vitamins	<b>Virt-Nate cap DHA</b>	Excluded	1/1/2023
Ophthalmic Agents- Drugs for Glaucoma	<b>Phospholine sol 0.125% OP</b>	Tier 3	1/1/2023
Immunomodulators	<b>Rinvoq tablet ER</b>	Tier 4	1/1/2023
Miscellaneous Therapeutic Agents	<b>Botox injection 100 unit, 200 unit</b>	Tier 3 PA	1/1/2023
Endocrine and Metabolic Agents	<b>sodium phenylbutyrate oral powder</b>	Tier 4 PA Added	1/1/2024
	<b>sodium phenylbutyrate tablet 500mg</b>	Tier 4 PA Added	1/1/2024
Miscellaneous Therapeutic Agents	<b>Argyle Saline solution 0.9% irrigation</b>	Excluded	1/1/2023
	<b>Curity Saline solution 0.9% irrigation</b>	Excluded	1/1/2023
Anti-hepatitis B (HBV) Agents	<b>Baraclude sol</b>	Tier 3 QL	1/1/2023
	<b>entecavir tab</b>	Tier 1 QL	
Anti-HIV Agents	<b>Epivir HBV sol 5mg/mL</b>	Tier 3	1/1/2023
	<b>lamivudine tab 100mg</b>	Tier 1	1/1/2023
Antivirals	<b>adefovir dipivoxil tab 10mg</b>	Tier 3	1/1/2023
Anticoagulants	<b>Enoxaparin injection</b>	Tier 3 QL	1/1/2023
	<b>Fondaparinux injection</b>	Tier 3 QL	1/1/2023

**Key**

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit CM=Oral Chemo  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status.  
Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

**YEAR-TO-DATE FORMULARY CHANGES**

<b>Therapeutic Class</b>	<b>Medication</b>	<b>Formulary Changes</b>	<b>Effective date</b>
Antineoplastic Enzyme Inhibitors	<b>Jakafi tablet 5mg</b>	CM QL Added	1/1/2023
Analgesics Anti-Inflammatory	<b>Xeljanz, Xeljanz XR</b>	Tier 4 QL Added	1/1/2023
Electrolytes/Mineral /Metals/Vitamins	<b>carglumic acid 200mg tablet</b> <i>(generic Carbaglu)</i>	Tier 4 Add PA	1/1/2023
Antimigraine Agents	<b>Ajovy injection 225mg/1.5 mL</b>	Tier 2 PA, QL	1/1/2023
	<b>Emgality injection 120mg/mL</b>	Excluded	1/1/2023
Antivirals	<b>Vemlidy tablet 25 mg</b>	Excluded	1/1/2023
Gastrointestinal Agents	<b>Dexilant DR capsule 30 mg, 60 mg</b>	Excluded	1/1/2023
	<b>dexlansoprazole DR capsule</b> <i>(authorized brand alternative Dexilant) 30 mg, 60 mg</i>	Excluded	1/1/2023
Antivirals	<b>Tamiflu</b>	Tier 3	1/1/2023-12/31/2023
Blood Products and Modifiers	<b>Procrit injection</b>	Tier 4	1/1/2023-12/31/2023

**Key**

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit CM=Oral Chemo  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status.  
Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.